LOS ANGELES (PRWEB)
June 18, 2020
David J. Dykeman, Ginger Pigott and Liberetta Stennes of global law firm Greenberg Traurig, LLP will be participating as panelists on a DeviceTalks Tuesday online panel discussion titled, “How COVID-19 is creating new IP and litigation challenges for medtechs” on June 16, 2020.
The June 16th event will discuss topics such as:
- IP strategy for companies innovating new technology or forming new collaborations
- Liability risks and immunity protections
- Impact of COVID-19 on litigation in the medtech industry
According to DeviceTalks’ website, the panel will provide information for entrepreneurs, investors, startup executives, medtech makers, design professionals, business development managers and anyone who wants to better understand how COVID-19 is affecting the med tech industry. In addition to Dykeman, Pigott, and Stennes, the panel will also include Jeff Mann, Senior Vice President, General Counsel and Secretary of Cantel Medical.
DeviceTalks, according to its website, is a “series of peer-led meetings created to help medtechs most innovative professionals find the quickest way to clear troublesome bottlenecks.”
Dykeman, who serves as co-managing shareholder of Greenberg Traurig’s Boston office and co-chairs the firm’s global Life Sciences & Medical Technology Group, is a registered patent attorney with more than 23 years of experience in patent and intellectual property law. His practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology.
Pigott, a shareholder in Greenberg Traurig’s Los Angeles office, is vice chair of the Pharmaceutical, Medical Device & Health Care Litigation Practice and focuses her practice on products liability litigation with an emphasis on the defense of complex medical device and pharmaceutical products. She handles high-stakes, single-plaintiff cases (including through trial) and complex litigation, including MDLs, coordinated state actions and class actions working as both national and regional counsel. She also works with companies to reduce and eliminate litigation risk and has been instrumental in achieving early resolution by way of alternative dispute resolution and dispositive motions in a number of cases.
Stennes, a shareholder in Greenberg Traurig’s Minneapolis office, litigates complex disputes, representing clients on matters related to environmental and mass tort defense, products liability and commercial disputes for clients in the food, agribusiness, chemical and life science industries. She guides clients through complex issues that arise from chemical exposures from products or environmental releases, particularly under emerging regulation.
About Greenberg Traurig’s Life Sciences & Medical Technology Group: Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from start-ups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing.
About Greenberg Traurig’s Pharmaceutical, Medical Device & Health Care Litigation Group: The Pharmaceutical, Medical Device & Health Care Litigation Group is an integral part of the firm’s 600+ attorney Litigation Practice. Led by “trial wizard” Lori G. Cohen, this team is nationally recognized for its dynamic courtroom presence, responsiveness to clients, and deep subject matter knowledge. Recent recognitions include the shortlist for Benchmark Litigation’s 2020 “Product Liability Firm of the Year”; national rankings for 2019 “Product Liability & Mass Torts” from Chambers USA Guide; and national rankings for 2019 “Product Liability, Mass Tort and Class Action Defense: Pharmaceuticals and Medical Devices” from The Legal 500 United States.
About Greenberg Traurig’s Litigation Practice: Greenberg Traurig’s Litigation Practice includes a team of more than 600 attorneys. The firm’s trial lawyers regularly appear in state and federal courts throughout the country, as well as in appellate courts and before international arbitration panels. They work closely with in-house counsel to develop a strategy that best fits a litigation cost and proficiency model appropriate to the client’s unique needs and goals.
About Greenberg Traurig, LLP: Greenberg Traurig, LLP (GT) has approximately 2200 attorneys in 41 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law.
Share article on social media or email: